Moderna clears near-term technical support, shares under pressure after recent rally

Moderna starts the week on the NASDAQ with shares giving back part of a strong 30-day gain, while traders watch technical support levels and the next earnings date at the end of July.

By Daniel Hoffmann, Chart & Technicals desk. Reviewed prior to publication on 2026-06-22, 18:38.

Moderna Inc. (US60770K1034) begins the new week on the NASDAQ with a mixed technical picture. After a marked 36 percent rise over the past 30 days, the focus now shifts to how robust current support levels remain ahead of the next earnings date at the end of July. TrendSpider market data

The technical setup for Moderna

On Monday, Moderna shares trade around the mid-60 dollar range, with recent data showing a last quote near 64 dollars and a 30-day performance up roughly 36 percent. TrendSpider market data Short-term indicators highlight that the stock has cleared immediate support levels that formed after the latest rally linked to renewed interest in its vaccine pipeline.

Chart services point to increased trading activity since mid-May, with volatility rising as headlines around infectious disease research and new vaccine data attracted traders’ attention. Finanzen100 overview For technically oriented investors, the question is whether the shares can hold above recent consolidation zones after the strong month-long advance.

What recent performance data show

In US trading, Moderna is currently quoted just below 64 dollars, with some intraday data indicating a decline of around 5 percent on Monday afternoon after the recent run-up. Morpher intraday snapshot The move gives back part of the gains that had pushed the stock sharply higher over the past weeks.

Over the last month, the biotech name has significantly outpaced many large pharmaceutical peers, supported by optimism around its mRNA vaccine programs and renewed focus on infectious disease candidates such as flu and hantavirus compared with companies like Novavax and Pfizer in the vaccine segment. Finviz news summary Market observers now emphasize that volatility remains high as the stock reprices on shifting expectations.

The business behind Moderna’s revenue

Moderna generates its revenue primarily from messenger-RNA-based vaccines and therapeutics, with its Covid-19 vaccine providing the bulk of historical sales. Simply Wall St company profile The company is expanding into seasonal flu, RSV and other infectious-disease vaccines, alongside exploratory programs in oncology and rare diseases.

Where the Moderna shares trade today

The Moderna shares (US60770K1034) trade on the NASDAQ at around 64.00 US dollars as of 2026-06-22, 16:00, after a volatile session that followed a strong month-long advance.

Key data on the Moderna shares

• Company: Moderna Inc.
• ISIN: US60770K1034
• WKN: A2N9D9
• Ticker: MRNA
• Trading venue: NASDAQ
• Price (as of 2026-06-22, 16:00): 64.00 USD
• Market cap: 25.0 billion USD (as of 2026-06-22)
• Sector / industry: Biotechnology / Pharmaceuticals
• Index membership: S&P 500
• Next earnings date: 2026-07-31

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities.